GSK plc (GSK) announced that it has signed an agreement with Massachusetts-based biopharmaceutical company Boston Pharmaceuticals to acquire the latter’s lead pipeline drug, efimosfermin alfa.Efimosfermin is an investigational long-acting variant of FGF21 protein designed to treat and prevent the progression of steatotic liver disease (SLD), commonly known as fatty liver disease. Boston Pharma is currently evaluating the drug in mid-stage studies for metabolic dysfunction-associated steatohepatitis (MASH), ...

Core Insights - iTeos Therapeutics and GSK have decided to terminate the belrestotug development program due to the failure to meet established criteria for clinically meaningful improvements in progression-free survival in the GALAXIES Lung-201 trial [1][3] - The GALAXIES Lung-201 trial showed clinically meaningful improvements in the primary endpoint of objective response rate (ORR), but did not meet criteria for the secondary endpoint of progression-free survival [2][3] - iTeos is initiating a targeted review of strategic alternatives to maximize shareholder value following the termination of the belrestotug program [3][4] Company Overview - iTeos Therapeutics is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapeutics [5] - The company is headquartered in Watertown, MA, with a research center in Gosselies, Belgium [5] Product Information - Belrestotug is a monoclonal antibody targeting TIGIT, designed to enhance the antitumor response through immune modulation [6]

- Topline interim dataset from GALAXIES Lung-201 with >240 patients anticipated in 2Q25 - Interim datasets from GALAXIES H&N-202 and TIG-006 HNSCC with ~200 patients anticipated in 2025 - Cash balance and investment balance of $624.3 million as of March 31, 2025 expected to provide runway through 2027 WATERTOWN, Mass. and GOSSELIES, Belgium, April 28, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new ...